BIOLASE, Inc.
BIOL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -6.1% | 14.1% | -24.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 40.4% | 39.9% | 32.9% | 26.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1.5% | -13.3% | -51.2% | -30.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13.2% | -24.2% | -64% | -39.5% |
| EPS Diluted | -0.04 | -0.084 | -0.36 | -1.76 |
| % Growth | 52.7% | 76.7% | 79.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |